Scientists trigger self-destruct switch in lung cancer cells
When healthy cells are no longer useful they initiate a chain of events culminating in self destruction. But cancer cells swerve away from this suicide path and become immortal. …
When healthy cells are no longer useful they initiate a chain of events culminating in self destruction. But cancer cells swerve away from this suicide path and become immortal. …
The research teams from the Walter and Eliza Hall Institute worked together to discover the three-dimensional structure of a key cell death protein called Bak and reveal the first steps in how it causes cell death. Their studies were published in Molecular Cell and Proceedings of the National Academy of Sciences. Programmed cell death, known as apoptosis, occurs naturally when the body has to remove unwanted cells. Chemical signals tell the cell to die by activating the apoptosis proteins Bak and Bax, which break down the ‘energy factory’ of the cell, known as the mitochondria. …
“Cells have genetic circuits that are used to switch certain behaviors on and off,” said biophysicist Eshel Ben-Jacob, a senior investigator at Rice’s Center for Theoretical Biological Physics and co-author of a new study in the Journal of the Royal Society Interface. “Though some of the circuits for metastasis have been mapped, this is the first study to examine how cancer uses two of those circuits, in concert, to produce not just cancer stem cells, but also dangerous packs of hybrid stem-like-cells that travel in groups to colonize other parts of the body.” Metastasis — the spread of cancer between organs — causes more than 90 percent of cancer deaths, but not all tumor cells can metastasize…
The National Cancer Institute (NCI) of the US National Institutes of Health (NIH) is supporting further clinical development of a new, improved, next-generation HPV vaccine. The vaccine was developed by a team led by Reinhard Kirnbauer from the Division of Immunodermatology at the MedUni Vienna in collaboration with Christina Schellenbacher and support from the Austrian Science Fund (FWF) and Vienna Science and Technology Fund (WWTF). The new vaccine had already demonstrated its excellent efficacy in a pre-clinical study in 2013…
So-called “triple-negative” breast cancer represents between 12 and 17 percent of all breast cancers. It derives its name from the lack of receptors for estrogen, progesterone and Her2…
The research, by an international team led by scientists from the McGill University and Genome Quebec Innovation Centre in Montreal, underscores the importance of investigating possible sources of exposure to aristolochic acid. The compound, found in plants of the Aristolochia genus, also has been suspected of causing a kidney disease known as Balkan endemic nephropathy, affecting people along the tributaries of the Danube River in Croatia, Bosnia and Herzegovina, Serbia, Bulgaria and Romania. Aristolochia clematitis, or European birthwort, is a common plant throughout the Balkans. Results of the study, which focused on the most common form of kidney cancer — clear-cell renal cell carcinoma — are reported in Nature Communications…
Enzymes like PRC1 turn on or turn off the activity of genes in a cell by manipulating individual chromosome units called nucleosomes. “The nucleosome is a key target of the enzymes that conduct genetic processes critical for life,” said Song Tan, professor of biochemistry and molecular biology at Penn State University and the leader of the study’s research team…
The study found that adding tomosynthesis (3D mammography) to routine biennial digital mammography screening among U.S. …
Wilms tumor is a rare childhood kidney cancer that can spread to the lungs. When this spread occurs, patients receive a relatively low dose of 12-14 Gray of radiation therapy to the entire chest. To see if such exposure to radiation affects patients’ risk of developing breast cancer, Norman Breslow, PhD, of the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, led a team that studied nearly 2500 young women who had been treated for Wilms tumor during childhood and who had survived until at least 15 years of age…
“Bortezomib helped a group of patients who desperately needed a treatment, having failed multiple different therapies,” said UC Davis hematologist and associate professor Mehrdad Abedi, lead author on the paper. “The drug fights chronic graft-versus host disease, and unlike other GVHD therapies such as steroid, cyclosporine or mycophenolate, it treats chronic GVHD without dampening the graft-versus-tumor effect, which can be critically important to help patients avoid relapse. In fact, because bortezomib is an anti-cancer drug, it potentially attacks cancer cells in its own right.” The trial results were published in October in the journal Blood. Chronic GVHD strikes patients who have received stem cell transplants from donors, commonly called allogeneic transplants. …